CFB
ALXN

Cullen/Frost Bankers’s Alexion Pharmaceuticals ALXN Stock Holding History

Cullen/Frost Bankers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3
Closed – – 1163
2020
Q4 		$0 Sell
3
-1
-25% -$129 ﹤0.01% 1211
2020
Q3 		$0 Buy
+4
New +$432 ﹤0.01% 1314
2019
Q3 		– Sell
-12
Closed -$2K – 1119
2019
Q2 		$2K Sell
12
-7
-37% -$902 ﹤0.01% 976
2019
Q1 		$3K Buy
+19
New +$2.36K ﹤0.01% 845

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cullen/Frost Bankers's ALXN Position: Q1 2021 in Review

Cullen/Frost Bankers sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 3 shares.

Cullen/Frost Bankers first reported a position in ALXN in Q1 2019 and held it in 4 quarters. The position peaked at $3K in Q1 2019. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Cullen/Frost Bankers reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Cullen/Frost Bankers sold 3 Alexion Pharmaceuticals shares in Q1 2021.
  • Cullen/Frost Bankers first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Cullen/Frost Bankers's Alexion Pharmaceuticals position peaked at $3K in Q1 2019.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Cullen/Frost Bankers's 13F filing for Q1 2021, filed 5 May 2021.